Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,993,448
  • Shares Outstanding, K 2,452,462
  • Annual Sales, $ 47,922 M
  • Annual Income, $ 6,016 M
  • EBIT $ 10,832 M
  • EBITDA $ 14,713 M
  • 60-Month Beta 0.48
  • Price/Sales 2.65
  • Price/Cash Flow 9.03
  • Price/Book 1.55

Options Overview Details

View History
  • Implied Volatility 22.86% ( +1.69%)
  • Historical Volatility 18.96%
  • IV Percentile 31%
  • IV Rank 14.45%
  • IV High 48.01% on 04/08/25
  • IV Low 18.61% on 02/20/25
  • Put/Call Vol Ratio 0.66
  • Today's Volume 252
  • Volume Avg (30-Day) 752
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 40,572
  • Open Int (30-Day) 39,601

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.98
  • Number of Estimates 7
  • High Estimate 1.05
  • Low Estimate 0.94
  • Prior Year 0.93
  • Growth Rate Est. (year over year) +5.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.42 +2.59%
on 06/18/25
49.42 -1.57%
on 07/10/25
+0.43 (+0.89%)
since 06/17/25
3-Month
47.42 +2.59%
on 06/18/25
55.73 -12.70%
on 05/02/25
-2.25 (-4.42%)
since 04/17/25
52-Week
45.80 +6.22%
on 12/16/24
60.12 -19.07%
on 03/10/25
-1.56 (-3.11%)
since 07/17/24

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY).  Such investors are advised...

SNY : 48.65 (+0.27%)
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months.  Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex generics,...

JNJ : 162.98 (-1.09%)
TEVA : 16.31 (+1.87%)
AMGN : 298.25 (-0.26%)
SNY : 48.65 (+0.27%)
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents close...

AZN : 69.26 (-1.17%)
MRK : 81.52 (-1.10%)
GSK : 36.47 (-4.73%)
SNY : 48.65 (+0.27%)
Will AbbVie's Acquisition Spree Aid Pipeline Growth?

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology remains its core area, the company is also signing some early-stage deals across...

LLY : 761.50 (-3.58%)
ABBV : 191.40 (+0.43%)
SNY : 48.65 (+0.27%)
Why This Wildcard Stock Could Be a Future Star

Recursion’s slow and steady start could lead to a bright future in biotech.

NVDA : 173.00 (+0.95%)
RXRX : 5.52 (+2.41%)
RHHBY : 39.8800 (-0.80%)
SNY : 48.65 (+0.27%)
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

REGN : 550.00 (+0.38%)
NKTR : 26.67 (+10.48%)
SNY : 48.65 (+0.27%)
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and...

AZN : 69.26 (-1.17%)
MRK : 81.52 (-1.10%)
REGN : 550.00 (+0.38%)
SNY : 48.65 (+0.27%)
Is Viatris Stock Underperforming the S&P 500?

Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s prospects.

$SPX : 6,297.36 (+0.54%)
VTRS : 9.27 (+2.09%)
SNY : 48.65 (+0.27%)
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?

Merck’s MRK second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human papillomavirus (HPV). Though the vaccine’s sales rose consistently till 2022,...

AZN : 69.26 (-1.17%)
MRK : 81.52 (-1.10%)
PFE : 24.58 (-0.12%)
SNY : 48.65 (+0.27%)
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery

The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets in April. With the massive tariffs imposed by the United States and...

BAYRY : 8.0800 (unch)
NVS : 114.52 (-3.25%)
ABBV : 191.40 (+0.43%)
PFE : 24.58 (-0.12%)
SNY : 48.65 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 49.48
2nd Resistance Point 49.06
1st Resistance Point 48.86
Last Price 48.65
1st Support Level 48.24
2nd Support Level 47.82
3rd Support Level 47.62

See More

52-Week High 60.12
Fibonacci 61.8% 54.65
Fibonacci 50% 52.96
Fibonacci 38.2% 51.27
Last Price 48.65
52-Week Low 45.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar